Presentation Information

[P109]Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits superior protective immunity against H5N1 high-pathogenicity avian influenza virus with reduced adverse reactions

Taro Shimizu1,2,3, Hiroki Tanaka3,4, Shintaro Shichinohe5, Toshiro Hirai1,2,3,6, Tokiko Watanabe3,5,7, Hidetaka Akita3,4, ○Yasuo Yoshioka1,2,3,6,7,8 (1. Vaccine Creation Group, Research Institute for Microbial Diseases, Osaka University (Japan), 2. OTRI, Osaka University (Japan), 3. CAMaD, Osaka University (Japan), 4. Graduate School of Pharmaceutical Sciences, Tohoku University (Japan), 5. Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University (Japan), 6. Graduate School of Pharmaceutical Sciences, Osaka University (Japan), 7. CiDER, Osaka University (Japan), 8. The Research Foundation for Microbial Diseases of Osaka University (Japan))

Password required to view


Comment

To browse or post comments, you must log in.Log in